BioAge Labs presented new data demonstrating how its drug candidate BGE-175 is uniquely poised to tackle age-related immune system decline that leads to disease progression.
An FDA Investigational New Drug application has been approved for NeuroSense Therapeutics Ltd.’s PrimeC, a potential therapeutic targeting amyotrophic lateral sclerosis (ALS).
At the Brigham and Women’s Hospital, a male patient with Secondary Progressive Multiple Sclerosis serves as a beacon of hope for those afflicted with the same neurodegenerative disease.
Akari announced that votucalis has potential as a treatment for pain and itch associated with conditions such as atopic dermatitis, psoriasis and neuropathic pain.
The single-shot chikungunya vaccine was shown to be safe and effective against mosquito-transmitted chikungunya disease in a published analysis of Phase III results.
Andrey Tolmachov issued a letter to the global drug discovery and scientific community, underscoring the importance of condemnation and action against Russian invasion.
